Development of Lyophilised Eudragit ® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration.

MLA

Lombardo, Rosamaria, et al. “Development of Lyophilised Eudragit ® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration.” Pharmaceutics, vol. 15, no. 5, May 2023. EBSCOhost, https://doi.org/10.3390/pharmaceutics15051554.

APA

Lombardo, R., Ruponen, M., Rautio, J., Ghelardini, C., Di Cesare Mannelli, L., Calosi, L., Bani, D., Lampinen, R., Kanninen, K. M., Koivisto, A. M., Penttilä, E., Löppönen, H., & Pignatello, R. (2023). Development of Lyophilised Eudragit ® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration. Pharmaceutics, 15(5). https://doi.org/10.3390/pharmaceutics15051554

Chicago

Lombardo, Rosamaria, Marika Ruponen, Jarkko Rautio, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Laura Calosi, Daniele Bani, et al. 2023. “Development of Lyophilised Eudragit ® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration.” Pharmaceutics 15 (5). doi:10.3390/pharmaceutics15051554.